

CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

DRAWN:

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID: MOREM020672181

Email: customercare.thane@srl.in

PATIENT NAME: MORE MANGESH MAHADEV

ACCESSION NO: 0181VI000338 AGE: 50 Years SEX: Male

RECEIVED: 10/09/2022 10:40 REPORTED: 14/09/2022 13:12

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units **Final**

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
METHOD: VISUAL INSPECTION			
APPEARANCE	CLEAR		
METHOD: VISUAL INSPECTION			
SPECIFIC GRAVITY	1.025	1.003 - 1.035	
METHOD: IONIC CONCENTRATION METHOD			
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN	15.6	13.0 - 17.0	g/dL
METHOD: SLS-HEMOGLOBIN DETECTION METHOD			
RED BLOOD CELL COUNT	4.97	4.5 - 5.5	mil/µL
METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION			
WHILE BLOOD CELL COUNT	9.51	4.0 - 10.0	thou/µL
METHOD: FLUORESCENCE FLOW CYTOMETRY			
PLATELET COUNT	306	150 - 410	thou/µL
METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION			
RBC AND PLATELET INDICES			
HEMATOCRIT	46.6	40.0 - 50.0	%
METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD			
MEAN CORPUSCULAR VOL	93.8	83.0 - 101.0	tL
METHOD: CALCULATED FROM RBC & HCT			
MEAN CORPUSCULAR HGB.	31.4	27.0 - 32.0	pg
METHOD: CALCULATED FROM THE RBC & HGB			
MEAN CORPUSCULAR HEMOGLOBIN	33.5	31.5 - 34.5	g/dL
CONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT			
MENTZER INDEX	18.9		
RED CELL DISTRIBUTION WIDTH	12.5	11.6 - 14.0	%
METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE			
MEAN PLATELET VOLUME	9.5	6.8 - 10.9	fL
METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMA	TOCRIT		
CHEMICAL EXAMINATION, URINE			
PH	6.0	4.7 - 7.5	
METHOD: DOUBLE INDICATOR PRINCIPLE			
PROTEIN	DETECTED (TRACE)	NOT DETECTED	



METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID

Page 1 Ot 12 Scan to View Report



CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: MORE MANGESH MAHADEV

PATIENT ID: MOREM020672181

ACCESSION NO: 0181VI000338 AGE: 50 Years SEX: Male

DRAWN: RECEIVED: 10/09/2022 10:40 REPORTED: 14/09/2022 13:12

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference Interva	al Units
GLUCOSE	NOT DETECTED		NOT DETECTED	
METHOD : GLUCOSE OXIDASE PEROXIDASE	NOI DETECTED		NOT DETECTED	
KETONES	NOT DETECTED		NOT DETECTED	
METHOD: NITROPRUSSIDE REACTION	NOT DETECTED		NOT DETECTED	
BLOOD	NOT DETECTED		NOT DETECTED	
METHOD: PEROXIDASE				
UROBILINOGEN	NORMAL		NORMAL	
METHOD: MODIFIED EHRLICH REACTION				
NITRITE	NOT DETECTED		NOT DETECTED	
METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL				
LEUKOCYTE ESTERASE	NOT DETECTED		NOT DETECTED	
WBC DIFFERENTIAL COUNT - NLR				
SEGMENTED NEUTROPHILS	52		40 - 80	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
ABSOLUTE NEUTROPHIL COUNT	4.95		2.0 - 7.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
LYMPHOCYTES	37		20 - 40	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
ABSOLUTE LYMPHOCYTE COUNT	3.50	High	1.0 - 3.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
NEUTROPHIL LYMPHOCYTE RATIC (NLR)	1.4			
EOSINOPHILS	6		1 - 6	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
ABSOLUTE EOSINOPHIL COUNT	0.53	High	0.02 - 0.50	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	_			
MONOCYTES	5		2 - 10	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	0.40		00.40	
ABSOLUTE MONOCYTE COUNT	0.43		0.2 - 1.0	thou/µL
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
DIFFERENTIAL COUNT PERFORMED ON:	EDTA SMEAR			
MICROSCOPIC EXAMINATION, URINE				
PUS CELL (WBC'S)	1-2		0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION	4.0		0.5	II IDE
EPITHELIAL CELLS	1-2		0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION	NOT DETECTED		NOT DETECTED	/LINE
ERYTHROCYTES (RBC'S) METHOD: MICROSCOPIC EXAMINATION	NOI DETECTED		NOT DETECTED	/HPF
CASTS	NOT DETECTED			
0.010	NOI DETECTED			







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 S.K. Tower, Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA

SRL Ltd

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID: MOREM020672181

Email: customercare.thane@srl.in

PATIENT NAME: MORE MANGESH MAHADEV

ACCESSION NO: 0181VI000338 AGE: 50 Years SEX: Male

DRAWN: RECEIVED: 10/09/2022 10:40 REPORTED: 14/09/2022 13:12

REFERRING DOCTOR: SFLF CLIENT PATIENT ID:

REFERRING DOCTOR: SELF	CLIENT PATIENT ID :		
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units	
METHOD: MICROSCOPIC EXAMINATION			
CRYSTALS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION			
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION			
YEAST	NOT DETECTED	NOT DETECTED	
REMARKS	PRECEINCE OF URIN	ARY PROTIEN RECHECK BY MANUAL METHOD.	
MORPHOLOGY			
RBC	NORMOCYTIC NORM	OCHROMIC	
WBC	NORMAL MORPHOLO	GY	
METHOD: MICROSCOPIC EXAMINATION			
PLATELETS	ADEQUATE		
ERYTHRO SEDIMENTATION RATE, BLOOD			
SEDIMENTATION RATE (ESR)	21	High 0 - 14 mm at 1 hr	

ERTTINO SEDIMENTATION NATE, DECOL			
SEDIMENTATION RATE (ESR)	21	High 0 - 14	mm at 1 hr
METHOD: WESTERGREN METHOD			
GLYCOSYLATED HEMOGLOBIN, EDTA WHO	LE BLOOD		
GLYCOSYLATED HEMOGLOBIN (HBA1C)	5.6	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or - 6.5	%

		Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0
METHOD: HPLC		
MEAN PLASMA GLUCOSE	114.0	< 116.0

MEAN PLASMA GLUCOSE	114.0	< 116.0	mg/dL
METHOD: CALCULATED PARAMETER			
GLUCOSE, FASTING, PLASMA			

GLUCOSE, FASTING, PLASMA	85	Normal 75 - 99	mg/dL
·		Pre-diabetics: 100 - 125	-

METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE	
--	--

GLUCOSE, POST-PRANDIAL, PLASMA		
GLUCOSE POST-PRANDIAL PLASMA	1∩7	70 - 139

GLUCOSE, POST-PRANDIAL, PLASMA	107	70 - 139	mg/dL
METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE			

CORONARY RISK PROFILE, SERUM CHOLESTEROL 150 Desirable cholesterol level

CHOLESTEROL 150 Desirable cholesterol level mg/dL < 200

Borderline high cholesterol

200 - 239 High cholesterol > / = 240

Diabetic: > or = 126

METHOD: ENZYMATIC COLORIMETRIC ASSAY







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg
THANE, 400602
MAHARASHTRA, INDIA
Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956
Email: customercare.thane@srl.in

PATIENT NAME: MORE MANGESH MAHADEV

PATIENT ID: MOREM020672181

ACCESSION NO: 0181VI000338 AGE: 50 Years SEX: Male

DRAWN: RECEIVED: 10/09/2022 10:40 REPORTED: 14/09/2022 13:12

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Inte	rval Units
TRIGLYCERIDES	105	Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY	24.4		
HDL CHOLESTEROL	34.4		mg/dL
CHOLESTEROL LDL	95		mg/dL
NON HDL CHOLESTEROL	116		mg/dL
CHOL/HDL RATIO	4.4		
LDL/HDL RATIO	2.8		
VERY LOW DENSITY LIPOPROTEIN	21.0	< OR = 30.0	mg/dL
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL	0.53	Upto 1.2	mg/dL
METHOD: COLORIMETRIC DIAZO			
BILIRUBIN, DIRECT	0.27	< 0.30	mg/dL
BILIRUBIN, INDIRECT	0.26	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD: COLORIMETRIC	7.7	6.0 - 8.0	g/dL
ALBUMIN	4.7	3.97 - 4.94	g/dL
METHOD: COLORIMETRIC			9, 42
GLOBULIN	3.0	2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.6	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: UV ABSORBANCE	27	< OR = 50	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV ABSORBANCE	23	< OR = 50	U/L
ALKALINE PHOSPHATASE METHOD: COLORIMETRIC	85	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: ENZYMATIC, COLORIMETRIC	31	0 - 60	U/L
LACTATE DEHYDROGENASE METHOD: UV ABSORBANCE	190	125 - 220	U/L
SERUM BLOOD UREA NITROGEN			
BLOOD UREA NITROGEN	11	6 - 20	mg/dL
METHOD: ENZYMATIC ASSAY	± ±	5 25	
CREATININE, SERUM			
CREATININE	1.10	0.7 - 1.2	mg/dL







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA

8800465156

SRL Ltd

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID: MOREM020672181

Email: customercare.thane@srl.in

PATIENT NAME: MORE MANGESH MAHADEV

ACCESSION NO: 0181VI000338 AGE: 50 Years SEX: Male

DRAWN: RECEIVED: 10/09/2022 10:40 REPORTED: 14/09/2022 13:12

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

METHOD : COLORIMETRIC BUN/CREAT RATIO 10.00 8.0 - 15.0 10.00	Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
BUN/CREAT RATIO 10.00 8.0 - 15.0 URIC ACID, SERUM LRIC ACID 7.2 High 3.4 - 7.0 mg/dL INCITAL PROTEIN, SERUM 7.7 6.0 - 8.0 g/dL ALBUMIN, SERUM 4.7 A.99 4.94 9/dL BLEUMIN, SERUM 4.7 4.94 9.7 4.94 9.7 4.94 9.7 6.0 - 8.0 9.7 6.0 - 8.0 9.7 9.7 4.94 9.7 4.94 9.7 6.0 - 8.0 9.7 4.94 9.7 9.7 4.94 9.7 4.94 9.7 4.94 9.7 4.94 9.7 9.7 9.7 9.7 9.7 9.7 9.7 9.7 </td <td>METHOD - COLORINGTON</td> <td></td> <td></td> <td></td> <td></td>	METHOD - COLORINGTON				
BUIN/CREAT RATIO 10.00 8.0 - 15.00 10					
URIC ACID, SERUM URIC ACID 7.2		10.00		9.0 - 15.0	
LRIC ACID 7.2 High 3.4 - 7.0 mg/dL METHOD: ENZYMATIC COLORIMETRIC ASSAY 7.7 6.0 - 8.0 g/dL TOTAL PROTEIN 7.7 6.0 - 8.0 g/dL METHOD: CCLORIMETRIC 7.7 3.97 - 4.94 g/dL ALBUMIN, SERUM 4.7 3.97 - 4.94 g/dL METHOD: CCLORIMETRIC 5.0 2.0 - 3.5 g/dL BOBULIN 3.0 2.0 - 3.5 g/dL BOBULIN 3.3 Low 36 - 145 mmol/L ELECTROLYTES (NA/K/CL), SERUM 133 Low 36 - 145 mmol/L POTASSIUM 5.19 High 3.5 - 5.1 mmol/L CHLORIDE 99 98 - 107 mmol/L WETHOD: ELECTROCHEMILUMINESCENCE 5.50 Low 80 - 200 mg/dL METHOD: ELECTROCHEMILUMINESCENCE 2.110 0.27 - 4.2 µI/L/mL METHOD: ELECTROCHEMILUMINESCENCE PRES P		10.00		8.0 - 15.0	
METHOD: ENZYMATIC COLORIMETRIC ASSAY TOTAL PROTEIN, SERUM TOTAL PROTEIN METHOD: COLORIMETRIC ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN ALBUMIN ALBUMIN ALBUMIN BCLOBULIN BCLOB		7.0	Uiab	2.4.7.0	
TOTAL PROTEIN, SERUM TOTAL PROTEIN METHOD: COLORIMETRIC ALBUMIN, SERUM 4 / 4 397 - 4.94 METHOD: COLORIMETRIC CLOBULIN GLOBULIN GLOBULIN SLOP - 3.5 GLOBULIN SODIUM SODIUM SODIUM POTASSILM CHICRIDE 99 169 170 mmol/L CHICRIDE THYROID PANEL, SERUM METHOD: ELECTROCHEMILUMINESCENCE THYROID PANEL, SERUM S.50		1.2	піуп	3.4 - 7.0	rrig/aL
TOTAL PROTEIN					
METHOD: COLORIMETRIC ALBUMIN, SERUM ALBUMIN		7 7		60-80	a/dl
### ALBUMIN		7.7		0.0 0.0	g, aL
### ALBUMIN					
METHOD: COLORIMETRIC GLOBULIN GLOBULIN 3.0 2.0 - 3.5 g/dL ELECTROLYTES (NA/K/CL), SERUM SODIUM 133 Low 136 - 145 mmol/L POTASSILM 5.19 High 3.5 - 5.1 mmol/L POTASSILM 99 3.5 - 5.1 mmol/L THYROID PANEL, SERUM T3 69.5 Low 80 - 200 mg/dL METHOD: ELECTROCHEMILUMINESCENCE T4 5.50 Low 80 - 200 mg/dL METHOD: ELECTROCHEMILUMINESCENCE T5H 3RD GENERATION 5.50 5.1 - 14.1 μg/dL METHOD: ELECTROCHEMILUMINESCENCE TSH 3RD GENERATION 2.110 0.27 - 4.2 μIU/mL METHOD: ELECTROCHEMILUMINESCENCE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD METHOD: GEL COLUMN AGGILUTINATION METHOD: METHOD: GEL COLUMN AGGILUTINATION METHOD: METHOD: GEL COLUMN AGGILUTINATION METHOD: TYPE 0 METHOD: GEL COLUMN AGGILUTINATION METHOD: TYPE	•	4. /		3.97 - 4.94	g/dL
GLOBULIN 3.0 2.0 - 3.5 g/dL ELECTROLYTES (NA/K/CL), SERUM SODIUM 133 Low 136 - 145 mmol/L POTASSIUM 5.19 High 3.5 - 5.1 mmol/L CHLORIDE 99 98 - 107 mmol/L THYROID PANEL, SERUM THYROID PANEL, SERUM THYROID PANEL, SERUM mmol/L T3 69.5 Low 80 - 200 ng/dL METHOD: ELECTROCHEMILUMINESCENCE 5.50 5.1 - 14.1 µg/dL METHOD: ELECTROCHEMILUMINESCENCE 2.110 0.27 - 4.2 µIU/mL ABO GROUP & RH TYPE, EDTA WHOLE BLOOD TYPE 0 TYPE 0 METHOD: GEL COLUMN AGGIUTINATION METHOD. POSITIVE TYPE 0 RH TYPE POSITIVE TYPE 0 XRAY-CHEST TYPE 0 TYPE 0 TMT OR ECHO NO ABNORMALITY DETECTED TYPE 0	METHOD: COLORIMETRIC				_
ELECTROLYTES (NA/K/CL), SERUM SODĪUM 133 Low 136 - 145 mmol/L POTASSĪUM 5.19 High 3.5 - 5.1 mmol/L CHLORIDE 99 98 - 107 mmol/L THYROID PANEL, SERUM T3 69.5 Low 80 - 200 ng/dL METHOD: ELECTROCHEMILUMINESCENCE 5.50 5.1 - 14.1 μg/dL METHOD: ELECTROCHEMILUMINESCENCE 2.110 0.27 - 4.2 μΙU/mL ABO GROUP & RH TYPE, EDTA WHOLE BLOOD TYPE O ΥΡΕΟ ΚΕΗ ΤΥΡΕ POSITIVE ΚΕΗ ΤΥΡΕ Κ	GLOBULIN				
SODIUM 133 Low 136 - 145 mmol/L POTASSIUM 5.19 High 3.5 - 5.1 mmol/L CHLORIDE 99 98 - 107 mmol/L THYROID PANEL, SERUM THYROID PANEL, SERUM THYROID PANEL, SERUM SERUM SERUM 80 - 200 ng/dL THYROID SELECTROCHEMILUMINESCENCE THYROID SELECTROCHEMILUMINESCENCE SERUM 5.50 5.1 - 14.1 µJU/mL METHOD: ELECTROCHEMILUMINESCENCE THYPE NETHOD: ELECTROCHEMILUMINESCENCE ABO GROUP THYPE, EDTA WHOLE BLOOD TYPE O METHOD: GEL COLUMN AGGIUTINATION METHOD. TYPE O METHOD: GEL COLUMN AGGIUTINATION METHOD. THYPE METHOD	GLOBULIN	3.0		2.0 - 3.5	g/dL
POTASSIUM 5.19 High 3.5 - 5.1 mmol/L CHLORIDE 99 98 - 107 mmol/L THYROID PANEL, SERUM 69.5 Low 80 - 200 ng/dL TS 69.5 Low 80 - 200 ng/dL METHOD: ELECTROCHEMILUMINESCENCE 5.50 5.1 - 14.1 µg/dL METHOD: ELECTROCHEMILUMINESCENCE 2.110 0.27 - 4.2 µIU/mL ABO GROUP & RH TYPE, EDTA WHOLE BLOOD TYPE O METHOD: GEL COLUMN AGGLUTINATION METHOD. POSITIVE METHOD: GEL COLUMN AGGLUTINATION METHOD. XRAY-CHEST IMPRESSION NO ABNORMALITY DETECTED TMT OR ECHO 2D ECHO: MILD CONCENTRIC LVH.	ELECTROLYTES (NA/K/CL), SERUM				
CHLORIDE 99 98 - 107 mmol/L THYROID PANEL, SERUM T3 69.5 Low 80 - 200 ng/dL METHOD: ELECTROCHEMILUMINESCENCE 5.50 5.1 - 14.1 µg/dL T4 5.50 0.27 - 4.2 µIU/mL METHOD: ELECTROCHEMILUMINESCENCE √ √ √ √ T5H 3RD GENERATION 2.110 0.27 - 4.2 µIU/mL √ METHOD: ELECTROCHEMILUMINESCENCE TYPE O ✓	SODIUM	133	Low	136 - 145	mmol/L
THYROID PANEL, SERUM T3	POTASSIUM	5.19	High	3.5 - 5.1	mmol/L
T3 Low 80 - 200 ng/dL METHOD : ELECTROCHEMILUMINESCENCE 5.50 5.1 - 14.1 µg/dL METHOD : ELECTROCHEMILUMINESCENCE 2.110 0.27 - 4.2 µIU/mL METHOD : ELECTROCHEMILUMINESCENCE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD TYPE 0 V	CHLORIDE	99		98 - 107	mmol/L
METHOD: ELECTROCHEMILUMINESCENCE 5.50 5.1 - 14.1 μg/dL METHOD: ELECTROCHEMILUMINESCENCE 2.110 0.27 - 4.2 μIU/mL METHOD: ELECTROCHEMILUMINESCENCE μIU/mL μETHOD: ELECTROCHEMILUMINESCENCE μIU/mL ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ΤΥΡΕ Ο ΚΕΝ ΤΥΡΕ <	THYROID PANEL, SERUM				
T4 5.50 5.1 - 14.1 μg/dL METHOD : ELECTROCHEMILUMINESCENCE 2.110 0.27 - 4.2 μIU/mL METHOD : ELECTROCHEMILUMINESCENCE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ΤΥΡΕ Ο ΥΕΡΕ Ο <t< td=""><td>Т3</td><td>69.5</td><td>Low</td><td>80 - 200</td><td>ng/dL</td></t<>	Т3	69.5	Low	80 - 200	ng/dL
METHOD : ELECTROCHEMILUMINESCENCE TSH 3RD GENERATION 2.110 0.27 - 4.2 µIU/mL METHOD : ELECTROCHEMILUMINESCENCE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP 6 COLUMN AGGLUTINATION METHOD. RH TYPE POSITIVE METHOD : GEL COLUMN AGGLUTINATION METHOD. XRAY-CHEST IMPRESSION NO ABNORMALITY DETECTED TMT OR ECHO 2D ECHO : MILD CONCENTRIC LVH.	METHOD: ELECTROCHEMILUMINESCENCE				
TSH 3RD GENERATION METHOD: ELECTROCHEMILLMINESCENCE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP METHOD: GEL COLUMN AGGLUTINATION METHOD. RH TYPE METHOD: GEL COLUMN AGGLUTINATION METHOD. XRAY-CHEST IMPRESSION NO ABNORMALITY DETECTED TMT OR ECHO 2D ECHO: MILD CONCENTRIC LVH.	T4	5.50		5.1 - 14.1	µg/dL
METHOD : ELECTROCHEMILLUMINESCENCE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP METHOD : GEL COLUMN AGGLUTINATION METHOD. RH TYPE METHOD : GEL COLUMN AGGLUTINATION METHOD. XRAY-CHEST IMPRESSION NO ABNORMALITY DETECTED TMT OR ECHO 2D ECHO : MILD CONCENTRIC LVH.					
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP METHOD: GEL COLUMN AGGLUTINATION METHOD. RH TYPE METHOD: GEL COLUMN AGGLUTINATION METHOD. XRAY-CHEST IMPRESSION NO ABNORMALITY DETECTED TMT OR ECHO 2D ECHO: MILD CONCENTRIC LVH.		2.110		0.27 - 4.2	μIU/mL
ABO GROUP METHOD: GEL COLUMN AGGLUTINATION METHOD. RH TYPE METHOD: GEL COLUMN AGGLUTINATION METHOD. XRAY-CHEST IMPRESSION NO ABNORMALITY DETECTED TMT OR ECHO 2D ECHO: MILD CONCENTRIC LVH.					
METHOD : GEL COLUMN AGGLUTINATION METHOD. RH TYPE METHOD : GEL COLUMN AGGLUTINATION METHOD. XRAY-CHEST IMPRESSION NO ABNORMALITY DETECTED TMT OR ECHO 2D ECHO : MILD CONCENTRIC LVH.		TYDE O			
RH TYPE METHOD: GEL COLUMN AGGLUTINATION METHOD. XRAY-CHEST IMPRESSION NO ABNORMALITY DETECTED TMT OR ECHO 2D ECHO: MILD CONCENTRIC LVH.		I IPE U			
METHOD : GEL COLUMN AGGLUTINATION METHOD. XRAY-CHEST IMPRESSION NO ABNORMALITY DETECTED TMT OR ECHO 2D ECHO : MILD CONCENTRIC LVH.		POSITIVE			
IMPRESSIONNO ABNORMALITY DETECTEDTMT OR ECHO2D ECHO : MILD CONCENTRIC LVH.		1 0011172			
TMT OR ECHO TMT OR ECHO 2D ECHO : MILD CONCENTRIC LVH.	XRAY-CHEST				
TMT OR ECHO 2D ECHO : MILD CONCENTRIC LVH.	IMPRESSION	NO ABNORMALITY DE	TECT	ED	
	TMT OR ECHO				
ECG	TMT OR ECHO	2D ECHO : MILD CON	ICENT	TRIC LVH.	
	ECG				
ECG T ABNORMALITY IN HIGH LATERAL LEADS.	ECG	T ABNORMALITY IN H	IGH L	LATERAL LEADS.	



Page 5 Ot 12 Scan to View Report



ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI 8800465156

DRAWN:

NEW DELHI 110030 DELHI INDIA

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: MORE MANGESH MAHADEV

<u>Final</u>

PATIENT ID:

MOREM020672181

ACCESSION NO: 0181VI000338 AGE: 50 Years

RECEIVED: 10/09/2022 10:40

REPORTED: 14/09/2022 13:12

REFERRING DOCTOR: SELF

CLIENT PATIENT ID: Biological Reference Interval

Units

MEDICAL HISTORY

Test Report Status

RELEVANT PRESENT HISTORY HYPERTENSIV & 1HD ON TREATMENT. RELEVANT PAST HISTORY H/O CAD ADMITTED IN HOSPITAL IN 2021.

40-50% LESION IN LAD - ON MEDICATIONS AT PRESENT.

RELEVANT PERSONAL HISTORY MARRIED / 2 CHILD / MIXED DIET / NO ALLERGIES / NO SMOKING /

Results

OCC ALCOHOL.

SEX: Male

NOT SIGNIFICANT RELEVANT FAMILY HISTORY

TAB.DEPLATT A 75: 1-0-0. HISTORY OF MEDICATIONS PROLOMET AM 50/5: 11-0-0.

TONACT 40MG: 0-0-1.

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.70 mts WEIGHT IN KGS. 84 Kgs

BMI 29 BMI & Weight Status as follows: kg/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obeše

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL PHYSICAL ATTITUDE NORMAL GENERAL APPEARANCE / NUTRITIONAL STATUS **OVERWEIGHT** BUILT / SKELETAL FRAMEWORK **AVERAGE** FACIAL APPEARANCE NORMAL SKIN NORMAL UPPER LIMB NORMAL LOWER LIMB NORMAL NECK NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED CAROTID PULSATION NORMAL **TEMPERATURE** NORMAL

PULSE 66/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

BRUIT

RESPIRATORY RATE NORMAL

CARDIOVASCULAR SYSTEM

130/80 MM HG mm/Hg

(SUPINE)

NORMAL PERICARDIUM







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID: MOREM020672181

Email: customercare.thane@srl.in

PATIENT NAME: MORE MANGESH MAHADEV

ACCESSION NO: 0181VI000338 AGE: 50 Years SEX: Male

DRAWN: RECEIVED: 10/09/2022 10:40 REPORTED: 14/09/2022 13:12

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

RETERRATIO DOCTOR: SELF		CEIENT PATIENT ID :	
Test Report Status <u>Final</u>	Results	Biological Reference Interval	Units
ADEX DE AT	NORMAL		
APEX BEAT	NORMAL		
HEART SOUNDS	NORMAL		
MURMURS	ABSENT		
RESPIRATORY SYSTEM	NODMAL		
SIZE AND SHAPE OF CHEST	NORMAL		
MOVEMENTS OF CHEST	SYMMETRICAL		
BREATH SOUNDS INTENSITY	NORMAL		
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)		
ADDED SOUNDS	ABSENT		
PER ABDOMEN	N.O.D.I.I.		
APPEARANCE	NORMAL		
VENOUS PROMINENCE	ABSENT		
LIVER	NOT PALPABLE		
SPLEEN	NOT PALPABLE		
HERNIA	ABSENT		
CENTRAL NERVOUS SYSTEM	NORMA		
HIGHER FUNCTIONS	NORMAL		
CRANIAL NERVES	NORMAL		
CEREBELLAR FUNCTIONS	NORMAL		
SENSORY SYSTEM	NORMAL		
MOTOR SYSTEM	NORMAL		
REFLEXES	NORMAL		
MUSCULOSKELETAL SYSTEM	NORMAL		
SPINE	NORMAL		
JOINTS	NORMAL		
BASIC EYE EXAMINATION			
CONJUNCTIVA	NORMAL		
EYELIDS	NORMAL		
EYE MOVEMENTS	NORMAL		
CORNEA	NORMAL		
DISTANT VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT		
DISTANT VISION LEFT EYE WITHOUT GLASSES	REDUCED VISUAL ACUITY	6/24	
DISTANT VISION RIGHT EYE WITH GLASSES	WITH GLASSES NORMAL		

REDUCED VISUAL ACUITY 6/12



DISTANT VISION LEFT EYE WITH GLASSES





ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

MOREM020672181

Email: customercare.thane@srl.in

PATIENT NAME: MORE MANGESH MAHADEV

ACCESSION NO: 0181VI000338 AGE: 50 Years SEX: Male

DRAWN: RECEIVED: 10/09/2022 10:40 REPORTED: 14/09/2022 13:12

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Biological Reference Interval **Test Report Status** Units <u>Final</u>

NEAR VISION RIGHT EYE WITHOUT GLASSES REDUCED VISUAL ACUITY N/36 NEAR VISION LEFT EYE WITHOUT GLASSES REDUCED VISUAL ACUITY N/36

NEAR VISION RIGHT EYE WITH GLASSES WITHIN NORMAL LIMIT

NEAR VISION LEFT EYE WITH GLASSES REDUCED VISUAL ACUITY N/12

COLOUR VISION NORMAL

SUMMARY

RELEVANT HISTORY NOT SIGNIFICANT OVERWEIGHT: BMI 29 RELEVANT GP EXAMINATION FINDINGS

REDUCED ACUITY FOR DISTANT AND NEAR VISION. 1) REGULAR FOLLOW UP WITH CARDIOLOGIST ADVISED. REMARKS / RECOMMENDATIONS

OPHTHALMOLOGY CONSULT FOR REDUCED VISUAL ACUITY.

3) AVOID HIGH QUALITY PROTEIN DIET. REGULAR WALK FOR 30 MINITS.

4) REPEAT S.ELECTROLYTES.URIC ACID.URIN ROUTINE AFTER 2

MONTHS OF DIET AND EXERCISE.

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-

The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

WBC DIFFERENTIAL COUNT - NLRThe optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculatec parameter and out of NABL scope.

MICROSCOPIC EXAMINATION, URINE-

Routine urine analysis assists in screening and diagnosis of various metabolic, urological, kidney and liver disorders

Protein: Elevated proteins can be an early sign of kidney disease. Unnary protein excretion can also be temporarily elevated by strenuous exercise, orthostatic proteinuria, dehydration, urinary tract infections and acute illness with fever Glucose: Uncontrolled diabetes mellitus can lead to presence of glucose in urine. Other causes include pregnancy, hormonal disturbances, liver disease and certain

medications.

Ketones: Uncontrolled diabetes mellitus car lead to presence of ketones in urine. Ketones can also be seen in starvation, frequent vomiting, pregnancy and strenuous exercise.

Blood: Occult blood can occur in urine as intact erythrocytes or haemoglobin, which can occur in various urological, nephrological and bleeding disorders. Leukocytes: An increase in leukocytes is an indication of inflammation in urinary tract or kidneys. Most common cause is bacterial urinary tract infection.

Nitritle: Many bacteria give positive results when their number is high. Nitritle concentration during infection increases with length of time the urine specimen is retained in bladder prior to collection.

pH: The kidneys play an important role in maintaining acid base balance of the body. Conditions of the body producing acidosis/ alkalosis or ingestion of certain type of food can affect the pH of urine.

Specific gravity: Specific gravity gives an indication of how concentrated the urine is. Increased specific gravity is seen in conditions like dehydration, glycosuria and proteinuria while decreased specific gravity is seen in excessive fluid intake, renal failure and diabetes insigndus.

Bilirubin: In certain liver diseases such as biliary obstruction or hepatitis, bilirubin gets excreted in urine.

Urobilinogen: Positive results are seen in liver diseases like hepatitis and cirrhosis and in cases of hemolytic anemia

ERYTHRO SEDIMENTATION RATE, BLOOD-

Erythrocyte sedimentation rate (ESR) is a non - specific phenomena and is clinically useful in the diagnosis and monitoring of disorders associated with an increased production of acute phase reactions. The ESR is increased in pregnancy from about the 3rd month and returns to normal by the 4th week post partum. ESR is influenced by age, sex, menstrual cycle and drugs (eg. corticosteroids, contraceptives). It is especially low (0-1mm) in polycythaemia, hypofibrinogenemia or congestive cardiac failure and when there are abnormalities of the redicells such as polkilocytosis, spherocytosis or sickle cells.

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition







ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030** DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: MORE MANGESH MAHADEV

PATIENT ID: MOREM020672181

ACCESSION NO: 0181VI000338 AGE: 50 Years SEX: Male

DRAWN: RECEIVED: 10/09/2022 10:40 REPORTED: 14/09/2022 13:12

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Biological Reference Interval Units Test Report Status <u>Final</u>

2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin
3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th Edition" GLYCOSYLATED HEMOGLOBIN, EDTA WHOLE BLOOD-

Glycosylatec hemoglobin (GHb) has been firmly established as an index of long-term blood glucose concentrations and as a measure of the risk for the development of complications in patients with diabetes mellitus. Formation of GHb is essentially irreversible, and the concentration in the blood depends on both the life span of the red blood cell (average 120 days) and the blood glucose concentration. Because the rate of formation of GHb is directly proportional to the concentration of glucose in the blood, the GHb concentration represents the integrated values for glucose over the preceding 6-8 weeks.

Any condition that afters the life span of the red blood cells has the potential to after the GHb level. Samples from patients with hemolytic anemias will exhibit decreased

any contained or actives one line span or the red productions are potential to after the OHO rever. Samples from patients with nemolytic anemias will exhibit decreased glycated hemoglobin values due to the shortened life span of the red cells. This effect will depend upon the severity of the anemia. Samples from patients with polycythemia or post-splenectomy may exhibit increased glycated hemoglobin values due to a somewhat longer life span of the red cells.

Glycosylated hemoglobins results from patients with HbSS, HbCC, and HbSC and HbD must be interpreted with caution, given the pathological processes, including anemia, increased red cell turnover, transfusion requirements, that adversely impact HbA1c as a marker of long-term glycemic control. In these conditions, alternative forms of testing such as glycated serum protein (fructosamine) should be considered.

'Targets should be individualized; More or less stringent glycemic goals may be appropriate for individual patients. Goals should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient

- 1. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, edited by Carl A Burtis, Edward R. Ashwood, David E Bruns, 4th Edition, Elsevier publication, 2006.
- 2. Forsham PH. Diabetes Mellitus: A rational plan for management. Postgrad Med 1982, 71,139-154.
 3. Mayer TK, Freedman ZR: Protein glycosylation in Diabetes Mellitus: A review of laboratory measurements and their clinical utility. Clin Chim Acta 1983, 127, 147-184. GLUCOSE, FASTING, PLASMA-

ADA 2021 guidelines for adults, after 8 hrs fasting is as follows: Pre-diabetics: 100 - 125 mg/dL

Diabetic: > or = 126 mg/dL

GLUCOSE, POST-FRANDIAL, PLASMA-ADA Guidelines for 2hr post prandial glucose levels is only after ingestion of 75grams of glucose in 300 ml water, over a period of 5

LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termec Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney, and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including the dual animality of the levels may be due to: Chronic inflammation or infection, including the paths B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumir constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc. SERUM BLOOD UREA NITROGEN-

Causes of Increased levels

Pre renal

- High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal
- Renal Failure

Malignancy, Nephrolithiasis, Prostatism

Causes of decreased levels

- Liver disease
- STADH

CREATININE, SERUM-



Page 9 Ot 12 Scan to View Report



ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

DELHI INDIA

SOUTH WEST DELHI **NEW DELHI 110030**

PATIENT NAME: MORE MANGESH MAHADEV

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956 Email: customercare.thane@srl.in 8800465156

> PATIENT ID: MOREM020672181

ACCESSION NO: 0181VI000338 AGE: 50 Years SEX: Male

DRAWN: RECEIVED: 10/09/2022 10:40 REPORTED: 14/09/2022 13:12

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Biological Reference Interval Test Report Status Units <u>Final</u>

SRL Ltd

THANE, 400602 MAHARASHTRA, INDIA

S.K. Tower, Hari Niwas, LBS Marg

Higher than normal level may be due to:

Blockage in the urinary tract
 Kidney problems, such as kidney damage or failure, infection, or reduced blood flow

Loss of body fluid (dehydration)

- Muscle problems, such as breakdown of muscle fibers
- · Problem's during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia GravisMuscular dystrophy

URIC ACID, SERUM-Causes of Increased levels

- Dietary

 High Protein Intake.
- Prolonged Fasting,
- Rapid weight loss

Gout

Lesch nyhan syndrome.

Type 2 DM. Metabolic syndrome.

Causes of decreased levels

- Low Zinc Intake OCP's
- · Multiple Sclerosis

Nutritional tips to manage increased Uric acid levels

- Drink plenty of fluids
- Limit animal proteinsHigh Fibre foods
- Vit C Intake
 Antioxidant rich foods
- TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-Josino enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ELECTROLYTES (NA/K/CL), SERUMSodium levels are Increased in dehydration, cushing's syndrome, aldosteronism & decreased in Addison's disease, hypopituitarism, liver disease. Hypokalemia (low K) is common in vomiting, diarrhea, alcoholism, folic acid deficiency and primary aldosteronism. Hyperkalemia may be seen in end-stage renal failure, hemolysis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid K infusion. Chloride is increased in dehydration, renal tubular acidosis (hyperchloremia metabolic acidosis), acute renal failure, metabolic acidosis associated with prolonged diarrhea and loss of sodium bicarbonate, diabetes insipidus, adrenocortical hyperfuction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt. Chloride is decreased in overhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis, congestive heart failure, Addisoniar crisis, certain types of metabolic acidosis, persistent gastric secretion and

respiratory additional reprinted in the blood inhibit the production of TSH.

Thyroxine T4, Thyroxine's principal function is to stimulate the metabolism of all cells and tissues in the body. Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the

2nd Trimester 6.6 - 15.50.2 **-** 3.0 0.3 **-** 3.0 100 - 260 100 - 260 6.6 - 15.5 3rc Trimester

Below mentioned are the guidelines for age related reference ranges for T3 and T4.



Т3

Page 10 Ot 12 回数 Scan to View Report



ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

ACCESSION NO: 0181VI000338

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower, Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

MOREM020672181

Email: customercare.thane@srl.in

PATIENT NAME: MORE MANGESH MAHADEV

AGE: 50 Years SEX: Male

DRAWN: RECEIVED: 10/09/2022 10:40 REPORTED: 14/09/2022 13:12

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units <u>Final</u>

(ng/dL) (µg/dL) 1-3 day: 8.2 - 19.9 1 Week: 6.0 - 15.9 New Born: 75 - 260

NOTE: TSH concentrations in apparently normal euthyroid subjects are known to be highly skewed, with a strong tailed distribution towards higher TSH values. This is well

documented in the pediatric population including the infant age group.

Kindly note: Method specific reference ranges are appearing or the report under biological reference range.

Reference:

1. Burtis C.A., Ashwood E. R. Bruns D.E. Teitz textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition.

2. Gowenlock A.H. Varley's Practical Clinical Biochemistry, 6th Edition.

3. Behrman R.E. Kilegman R.M., Jenson H. B. Nelson Text Book of Pediatrics, 17th Edition

ABO GROUP 8. RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Flease note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.







CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd S.K. Tower,Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: MORE MANGESH MAHADEV

MOREM020672181

ACCESSION NO: 0181VI000338

AGE: 50 Years

SEX: Male

REPORTED:

14/09/2022 13:12

DRAWN:

REFERRING DOCTOR: SELF

RECEIVED: 10/09/2022 10:40

CLIENT PATIENT ID:

Test Report Status

Final

Results

Biological Reference Interval Units

PATIENT ID:

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN GRADE | FATTY LIVER.

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

Dr.Priyal Chinchkhede Consultant Pathologist

Dhindhehede

Dr. Ushma Wartikar Consultant Pathologist Dr.(Mrs)Neelu K Bhojani

. Lab Head





Page 12 Ot 12